Skip to main navigation Skip to search Skip to main content

Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes

  • Lőrinc Sándor Pongor
  • , Christopher W Schultz
  • , Lorenzo Rinaldi
  • , Darawalee Wangsa
  • , Christophe E Redon
  • , Nobuyuki Takahashi
  • , Gavriel Fialkoff
  • , Parth Desai
  • , Yang Zhang
  • , Sandra Burkett
  • , Nadav Hermoni
  • , Noa Vilk
  • , Jenia Gutin
  • , Rona Gergely
  • , Yongmei Zhao
  • , Samantha Nichols
  • , Rasa Vilimas
  • , Linda Sciuto
  • , Chante Graham
  • , Juan Manuel Caravaca
  • Sevilay Turan, Shen Tsai-Wei, Vinodh N Rajapakse, Rajesh Kumar, Deep Upadhyay, Suresh Kumar, Yoo Sun Kim, Nitin Roper, Bao Tran, Stephen M Hewitt, David E Kleiner, Mirit I Aladjem, Nir Friedman, Gordon L Hager, Yves Pommier, Thomas Ried, Anish Thomas
  • National Cancer Institute
  • Developmental Therapeutics Branch
  • Hebrew University of Jerusalem
  • Department of Biochemistry and Molecular Pharmacology
  • Bioinformatics and Computational Science Directorate
  • New York University Langone Health Perlmutter Cancer Center and Grossman School of Medicine
  • Cancer Research Technology Program

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer. Onco-genic MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC amplification and phenotypic plasticity, characterized by neuroendocrine and nonneuroen-docrine cell states, are not known. Here, we integrate whole-genome sequencing, long-range optical mapping, single-cell DNA sequencing, and fluorescence in situ hybridization to find extrachromosomal DNA (ecDNA) as a primary source of SCLC oncogene amplifications and driver fusions. ecDNAs bring to proximity enhancer elements and oncogenes, creating SCLC transcription-amplifying units, driving exceptionally high MYC gene dosage. We demonstrate that cell-free nucleosome profiling can nonin-vasively detect ecDNA amplifications in plasma, facilitating its genome-wide interrogation in SCLC and other cancers. Altogether, our work provides the first comprehensive map of SCLC ecDNA and describes a new mechanism that governs MYC-driven SCLC heterogeneity. ecDNA-enabled transcriptional flexibility may explain the significantly worse survival outcomes of SCLC harboring complex ecDNA amplifications.

Original languageEnglish
Pages (from-to)928-949
Number of pages22
JournalCancer Discovery
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Humans
  • Small Cell Lung Carcinoma/genetics
  • In Situ Hybridization, Fluorescence
  • Lung Neoplasms/genetics
  • Oncogenes
  • DNA
  • Gene Amplification

Fingerprint

Dive into the research topics of 'Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes'. Together they form a unique fingerprint.

Cite this